Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sunshine Biopharma's Nora Pharma Receives Approval for Niopeg(R) Biosimilar
Details : Niopeg (pegfilgrastim) is an FDA-approved G-CSF agonist for treating febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.
Brand Name : Niopeg
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 19, 2024
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?